Stockpolly
Search
MIST · NASDAQ · Biotechnology

Milestone Pharmaceuticals (MIST)

Commercializes an etripamil nasal spray for acute adult PSVT episodes.

$1.18
Pre-market+0.00 (+0.34%)
At close$1.18(+3.51%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000201
Cost of revenue000000000000
Gross profit000000000201
151410101012211312192426
Research & development754344544634
987768169813523
Selling & marketing4532241055800
General & administrative4345445435523
Other expenses0000000000160
Operating income−15−14−10−10−10−12−21−13−12−17−24−26
0000000000−2−3
Interest income111111111122
Interest expense111111111145
Other non-operating income−1−1−1−1−1−1−1−1−1−1−2−2
Income before tax−15−14−10−9−9−12−21−13−12−17−26−29
Income tax expense000000000000
Net income from continuing operations−15−14−10−9−9−12−21−13−12−17−26−29
Net income−15−14−10−9−9−12−21−13−12−17−26−29
EPS, basic−$0.35−$0.41−$0.21−$0.14−$0.14−$0.20−$0.31−$0.20−$0.12−$0.16−$0.20−$0.21
EPS, diluted−$0.35−$0.41−$0.21−$0.14−$0.14−$0.20−$0.31−$0.20−$0.12−$0.16−$0.20−$0.21
Weighted average shares, basic43335066666266666684130139
Weighted average shares, diluted43335066666266666684130139
EBITDA−14−13−9−8−9−11−20−12−11−16−22−24
Depreciation & amortization000000000000
EBIT−14−13−9−8−9−11−20−12−11−16−22−24